Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Declines By 13.8%

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 1,620,000 shares, a decline of 13.8% from the March 15th total of 1,880,000 shares. Currently, 2.0% of the shares of the company are sold short. Based on an average daily trading volume, of 485,500 shares, the short-interest ratio is presently 3.3 days.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX traded down $0.01 during trading on Tuesday, reaching $1.57. The company had a trading volume of 718,709 shares, compared to its average volume of 499,996. The firm’s fifty day moving average is $1.84 and its 200 day moving average is $1.73. The firm has a market capitalization of $216.02 million, a PE ratio of -4.62 and a beta of 0.78. Compass Therapeutics has a twelve month low of $1.15 and a twelve month high of $3.62.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, March 21st. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Equities analysts predict that Compass Therapeutics will post -0.48 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

Institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its holdings in Compass Therapeutics by 577.2% during the first quarter. Tower Research Capital LLC TRC now owns 7,855 shares of the company’s stock worth $26,000 after acquiring an additional 6,695 shares during the period. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics in the 2nd quarter worth approximately $35,000. Alliancebernstein L.P. bought a new stake in shares of Compass Therapeutics in the 2nd quarter worth approximately $36,000. UBS Group AG lifted its stake in Compass Therapeutics by 63.5% during the fourth quarter. UBS Group AG now owns 11,819 shares of the company’s stock valued at $59,000 after purchasing an additional 4,591 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in Compass Therapeutics during the second quarter worth approximately $38,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a report on Friday, March 22nd.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.